XML 52 R19.htm IDEA: XBRL DOCUMENT

Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2020

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

Product revenue, net was as follows (in thousands):

	Three Months Ended March 31, 2020
Gross revenue	$	5,372
Contractual sales rebate		(376	)
Key account hospital sales rebate		(27	)
Transfer fee discount		(14	)
Product revenue, net	$	4,955

Summary of Accounts Receivable Allowances Related to Product Revenue

The following table is a roll-forward of accounts receivable allowances related to product revenue:

	Balance at December 31, 2019		Current Period Additions		Credits / Payments		Balance at March 31, 2020
Price adjustment	$	936	$	—	$	—	$	936
Contractual sales rebate		148		376		—		524
Key account hospital sales rebate		12		27		—		39
Transfer fee discount		6		14		—		20
Total	$	1,102	$	417	$	—	$	1,519

Japan [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Performance Obligation	2020		2019
Japan	License revenue	$	—	$	—
	Development revenue	$	163	$	246

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

Japan Agreement	Cumulative Revenue Through March 31, 2020		Deferred Revenue at March 31, 2020		Total Consideration Through March 31, 2020
License	$	86,024	$	—	$	86,024
Development revenue		15,293		269		15,562
Total license and development revenue	$	101,317	$	269	$	101,586

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Performance Obligation	2020		2019
Europe	License revenue	$	—	$	—
	Development revenue	$	4,574	$	4,613

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

Europe Agreement	Cumulative Revenue Through March 31, 2020		Deferred Revenue at March 31, 2020			Total Consideration Through March 31, 2020
License	$	487,951	$	—		$	487,951
Development revenue		235,582		3,442			239,024
Total license and development revenue	$	723,533	$	3,442	*	$	726,975

_______________________________________________________________________________________________________

Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the condensed consolidated balance sheets. As of March 31, 2020, prepaid expenses and other current assets included a net unbilled contract asset of $126.6 million related to the Europe Agreement, which represents the net of the above-mentioned unbilled contract asset of $130.0 million, and $3.4 million of deferred revenue presented above.

U.S./RoW and China [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended March 31,
Agreement	Performance Obligation	2020		2019
U.S. / RoW and China	License revenue	$	—	$	—
	Development revenue		14,556		19,004
	China performance obligation	$	153	$	—

Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue

The transaction price related to consideration received and accounts receivable has been allocated to each of the following performance obligations under the U.S./RoW Agreement and China Agreement, along with any associated deferred revenue as follows (in thousands):

U.S. / RoW and China Agreements	Cumulative Revenue Through March 31, 2020		Deferred Revenue at March 31, 2020		Total Consideration Through March 31, 2020
License	$	341,844	$	—	$	341,844
Co-development, information sharing & committee services		507,822		6,323		514,145
China performance obligation		243		141,079		141,322
Total license and development revenue	$	849,909	$	147,402	$	997,311